Literature DB >> 18308005

Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus.

Xilin Yang1, Wing-Yee So, Alice P S Kong, Ronald C W Ma, Gary T C Ko, Chung-Shun Ho, Christopher W K Lam, Clive S Cockram, Juliana C N Chan, Peter C Y Tong.   

Abstract

There are no validated risk scores for predicting coronary heart disease (CHD) in Chinese patients with type 2 diabetes mellitus. This study aimed to validate the UKPDS risk engine and, if indicated, develop CHD risk scores. A total of 7,067 patients without CHD at baseline were analyzed. Data were randomly assigned to a training data set and a test data set. Cox models were used to develop risk scores to predict total CHD in the training data set. Calibration was assessed using the Hosmer-Lemeshow test, and discrimination was examined using the area under the receiver-operating characteristic curve in the test data set. During a median follow-up of 5.40 years, 4.97% of patients (n = 351) developed incident CHD. The UKPDS CHD risk engine overestimated the risk of CHD with suboptimal discrimination, and a new total CHD risk score was developed. The developed total CHD risk score was 0.0267 x age (years) - 0.3536 x sex (1 if female) + 0.4373 x current smoking status (1 if yes) + 0.0403 x duration of diabetes (years) - 0.4808 x Log(10) (estimated glomerular filtration rate [ml/min/1.73 m(2)]) + 0.1232 x Log(10) (1 + spot urinary albumin-creatinine ratio [mg/mmol]) + 0.2644 x non-high-density lipoprotein cholesterol (mmol/L). The 5-year probability of CHD = 1 - 0.9616(EXP(0.9440 x [RISK SCORE - 0.7082])). Predicted CHD probability was not significantly different from observed total CHD probability, and the adjusted area under the receiver-operating characteristic curve was 0.74 during 5 years of follow-up. In conclusion, the UKPDS CHD risk engine overestimated the risk of Chinese patients with type 2 diabetes mellitus and the newly developed total CHD risk score performed well in the test data set. External validations are required in other Chinese populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18308005     DOI: 10.1016/j.amjcard.2007.10.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  37 in total

1.  Diabetes, insulin and cancer risk.

Authors:  Xi-Lin Yang; Juliana Cn Chan
Journal:  World J Diabetes       Date:  2012-04-15

Review 2.  Toward Big Data Analytics: Review of Predictive Models in Management of Diabetes and Its Complications.

Authors:  Simon Lebech Cichosz; Mette Dencker Johansen; Ole Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2015-10-14

3.  Cardiovascular Disease Incidence and Risk Factor Patterns among Omanis with Type 2 Diabetes: A Retrospective Cohort Study.

Authors:  Abdul Hakeem Al Rawahi; Patricia Lee; Zaher A M Al Anqoudi; Ahmed Al Busaidi; Muna Al Rabaani; Faisal Al Mahrouqi; Ahmed M Al Busaidi
Journal:  Oman Med J       Date:  2017-03

4.  From design to implementation--the Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program.

Authors:  Gary T Ko; Wing-Yee So; Peter C Tong; Francois Le Coguiec; Debborah Kerr; Greg Lyubomirsky; Beaver Tamesis; Troels Wolthers; Jennifer Nan; Juliana Chan
Journal:  BMC Med Inform Decis Mak       Date:  2010-05-13       Impact factor: 2.796

Review 5.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

6.  Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect.

Authors:  Wei-Jei Lee; Keong Chong; Yu-Hung Lin; Jih-Hua Wei; Shu-Chun Chen
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

7.  Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study).

Authors:  Jorge R Kizer; Daniel G Krauser; Richard J Rodeheffer; John C Burnett; Peter M Okin; Mary J Roman; Jason G Umans; Lyle G Best; Elisa T Lee; Richard B Devereux
Journal:  Am J Cardiol       Date:  2009-06-03       Impact factor: 2.778

8.  Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.

Authors:  Wilson Y Leung; Wing-yee So; Derek Stewart; Augustine Lui; Peter C Tong; Gary T Ko; Alice P Kong; Ronald C Ma; Francis K Chan; Xilin Yang; Sau-chu Chiang; Juliana C Chan
Journal:  Cardiovasc Diabetol       Date:  2009-10-30       Impact factor: 9.951

9.  Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study.

Authors:  Amber A W A van der Heijden; Monica M Ortegon; Louis W Niessen; Giel Nijpels; Jacqueline M Dekker
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 10.  Cardiovascular risk assessment scores for people with diabetes: a systematic review.

Authors:  P Chamnan; R K Simmons; S J Sharp; S J Griffin; N J Wareham
Journal:  Diabetologia       Date:  2009-07-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.